About This Video
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled “Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.
To view Multimedia News Release, go to http://www.prnewswire.com/mnr/pvct/37868/
This website uses Adobe® Flash™ Player 9
Download Flash Now
If you are using Internet Explorer, you will need to restart your browser
after installing Flash.
Adobe and Flash are registered trademarks of Adobe Systems incorporated.
All rights reserved.
